Similarly, fimepinostat (CUDC-907) is a dual inhibitor of HDAC and PI3K that can be used in combination with VTC in AML, whereas bisantrene is a topoisomerase-II inhibitor that can act as a HDAC inhibitor when combined with VTC and panobinostat (79, 80). Here, HDAC9 is linked to acute myeloid leukemia.